These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 32405322)

  • 1. Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis.
    Jin H; Zhu K; Wang L; Li Y; Meng J; Zhi H
    Cardiovasc Ther; 2020; 2020():2683740. PubMed ID: 32405322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis.
    Jin H; Zhu K; Wang L; Zhou W; Zhi H
    Thromb Res; 2020 Dec; 196():109-119. PubMed ID: 32861151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A network meta-analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus.
    Jin H; Zhu K; Wang L; Zhi H
    Acta Cardiol; 2021 Nov; 76(9):960-969. PubMed ID: 33432890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation.
    Zhou LY; Yang SF; Zhang Z; Zhang C; Shen L; Gu ZC; Zuo XC
    Front Physiol; 2018; 9():1644. PubMed ID: 30524307
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
    Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
    Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
    Ma F; Xu W; Chen J; Zhang J
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1013-1022. PubMed ID: 37310479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer-a network meta-analysis.
    Yang P; Zhu D; Xu X; Shen W; Wang C; Jiang Y; Xu G; Wu Q
    Heart Fail Rev; 2020 Sep; 25(5):823-831. PubMed ID: 31410758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis.
    Andò G; Capranzano P
    Int J Cardiol; 2017 Mar; 231():162-169. PubMed ID: 28007305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis.
    Antza C; Doundoulakis I; Akrivos E; Economou F; Vazakidis P; Haidich AB; Kotsis V
    Scand Cardiovasc J; 2019 Apr; 53(2):48-54. PubMed ID: 30896311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis.
    Wang Z; Xiang Q; Hu K; Zhang X; Xie Q; Liu Z; Cui Y
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):643-657. PubMed ID: 33817758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
    Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
    Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
    Wang X; Wang T; Chen X; Tian W; Ma D; Zhang J; Li Q; Chen Z; Ju J; Xu H; Chen K
    J Am Med Dir Assoc; 2023 Aug; 24(8):1233-1239.e26. PubMed ID: 37355246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.